{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T19:13:08Z","timestamp":1780686788145,"version":"3.54.1"},"reference-count":133,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>T-cell engagers represent a transformative approach to cancer immunotherapy leveraging bispecific and multispecific antibody constructs to redirect T-cell cytotoxicity toward malignant cells. These molecules bridge T cells and tumor cells by simultaneously binding CD3 on T cells and tumor-associated antigens on cancer cells, thereby enabling precise immune targeting even in immunologically \u201ccold\u201d tumors. Recent advancements include conditional T-cell engagers activated by tumor microenvironment proteases to minimize off-tumor toxicity as well as T-cell receptor\u2013based engagers targeting intracellular antigens via MHC presentation. Clinical successes, such as Kimmtrak in metastatic uveal melanoma, underscore good potential of these modalities, while challenges persist in the management of cytokine release syndrome, neurotoxicity, and tumor resistance. Emerging multispecific engagers are aimed at enhancing efficacy via incorporation of costimulatory signals, thus offering a promising trajectory for next-generation immunotherapies. T-cell engagers are also gaining attention in the treatment of autoimmune disorders, where they can be designed to selectively modulate pathogenic immune responses. By targeting autoreactive T or B cells, T-cell engagers hold promise for restoring immune tolerance in such conditions as HLA-B*27\u2013associated autoimmunity subtypes, multiple sclerosis, rheumatoid arthritis, and type 1 diabetes mellitus. Engineering strategies that incorporate inhibitory receptors or tissue-specific antigens may further refine T-cell engagers\u2019 therapeutic potential in autoimmunity, by minimizing systemic immunosuppression while preserving immune homeostasis.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1551424","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:16:25Z","timestamp":1746504985000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Engaging T cells for cleanup"],"prefix":"10.3389","volume":"16","author":[{"given":"Roman V.","family":"Mungalov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia V.","family":"Mushenkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitriy M.","family":"Chudakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Turchaninova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2108","article-title":"A novel B7-H6\u2013targeted igG-like T cell\u2013engaging antibody for the treatment of gastrointestinal tumors","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01704-4","article-title":"Tebentafusp: first approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics13101669","article-title":"A strategy for selective deletion of autoimmunity-related t cells by pmhc-targeted delivery","volume":"13","author":"Goldberg","year":"2021","journal-title":"Pharmaceutics"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1494","article-title":"Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers","volume":"9","author":"Parkhurst","year":"2019","journal-title":"Cancer Discovery"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae136","article-title":"Lifileucel : FDA-approved T-cell therapy for melanoma","volume":"2","author":"Kwong","year":"2024","journal-title":"The Oncologist"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1334","article-title":"Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non-small cell lung cancer resistant to immune checkpoint inhibitors","volume":"14","author":"Schoenfeld","year":"2024","journal-title":"Cancer Discovery"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008645","article-title":"Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes","volume":"12","author":"Levin","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.77274","article-title":"Pinpointing the tumor-specific T cells via TCR clusters","volume":"11","author":"Goncharov","year":"2022","journal-title":"Elife"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000341","article-title":"Cardiovascular toxicity and mortality associated with adoptive cell therapy and tumor-infiltrating lymphocytes for advanced stage melanoma","volume":"44","author":"Fradley","year":"2021","journal-title":"J Immunother"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02572-1","article-title":"Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial","volume":"69","author":"Khammari","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.809754","article-title":"In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy","volume":"12","author":"Xin","year":"2022","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-024-00150-z","article-title":"In vivo CAR T cells move into clinical trials","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat Rev Drug Discovery"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0278-6","article-title":"CAR-T cells: The long and winding road to solid tumors","volume":"9","author":"D\u2019Aloia","year":"2018","journal-title":"Cell Death and Disease"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030663","article-title":"CAR-T: what is next","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary Malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02250","article-title":"Engineered T cell therapy for cancer in the clinic","volume":"10","author":"Zhao","year":"2019","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1489827","article-title":"Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors","volume":"15","author":"Khan","year":"2024","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-024-03315-3","article-title":"Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006292","article-title":"Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering","volume":"11","author":"Michels","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.AAZ1863","article-title":"Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors","volume":"12","author":"Park","year":"2020","journal-title":"Sci Trans Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.03.018","article-title":"Viral delivery of CAR targets to solid tumors enables effective cell therapy","volume":"17","author":"Aalipour","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004167","article-title":"Remodeling the tumor microenvironment by oncolytic viruses: Beyond oncolysis of tumor cells for cancer treatment","volume":"10","author":"Wang","year":"2022","journal-title":"J ImmunoTherapy Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.561372","article-title":"Remodeling of tumor immune microenvironment by oncolytic viruses","volume":"10","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by Malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1472772","article-title":"Advances in targeting tumor microenvironment for immunotherapy","volume":"15","author":"Wang","year":"2024","journal-title":"Frontiers in Immunology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: State of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci Adv"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040743","article-title":"Adoptive immunotherapy beyond CAR T-cells","volume":"13","author":"Titov","year":"2021","journal-title":"Cancers"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10948-w","article-title":"Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T","volume":"10","author":"Nerreter","year":"2019","journal-title":"Nature Communications"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A pilot trial using lymphocytes genetically engineered with an NY-ESO-1\u2013reactive T-cell receptor: long-term follow-up and correlates with response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008668","article-title":"First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors","volume":"12","author":"Wermke","year":"2024","journal-title":"J ImmunoTherapy Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000194","article-title":"Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma","volume":"3","author":"Stadtmauer","year":"2019","journal-title":"Blood Adv"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01225-1","article-title":"TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers","volume":"27","author":"Nagarsheth","year":"2021","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"New Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"215840","DOI":"10.1016\/j.canlet.2022.215840","article-title":"Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application","volume":"546","author":"Xu","year":"2022","journal-title":"Cancer Letters"},{"key":"B38","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1038\/s41467-023-42010-1","article-title":"KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors","volume":"14","author":"Lu","year":"2023","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0978","article-title":"Lymph node-targeted vaccine boosting of TCR T-cell therapy enhances antitumor function and eradicates solid tumors","volume":"12","author":"Drakes","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08657-0","article-title":"HIV immune evasin Nef enhances allogeneic CAR T cell potency","volume":"22","author":"Perica","year":"2025","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115658","article-title":"How TCRs bind MHCs, peptides, and coreceptors","volume":"24","author":"Rudolph","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological Malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","article-title":"Tarlatamab","volume":"84","author":"Dhillon","year":"2024","journal-title":"First approval Drugs"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000847716.29326.a8","article-title":"Subcutaneous epcoritamab with GemOX induced high response rates in patients with relapsed\/refractory diffuse large B-cell lymphoma ineligible for autologous stem cell transplant","volume":"6","author":"Wahlin","year":"2022","journal-title":"HemaSphere"},{"key":"B45","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies \u2014 BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01176-4","article-title":"Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases","volume":"21","author":"Rolin","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1759055","article-title":"Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"61","author":"Coyle","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010956","article-title":"Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed\/refractory acute myeloid leukemia","volume":"7","author":"Ravandi","year":"2023","journal-title":"Blood Adv"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095517","article-title":"Characterization of a novel single-chain bispecific antibody for retargeting of T Cells to tumor cells via the TCR co-receptor CD8","volume":"9","author":"Michalk","year":"2014","journal-title":"PloS One"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2023.104787","article-title":"Anti-CD19\/CD8 bispecific T cell engager for the potential treatment of B cell Malignancies","author":"Maghsoodi","year":"2023","journal-title":"Cell Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011858","article-title":"Dual-targeting CD33\/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile","volume":"8","author":"Zeng","year":"2024","journal-title":"Blood Adv"},{"key":"B54","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/toxsci\/kfac052","article-title":"Characterization of an anti-CD70 half-life extended bispecific T-cell engager (HLE-biTE) and associated on-target toxicity in cynomolgus monkeys","volume":"189","author":"Harper","year":"2022","journal-title":"Toxicological Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41557-023-01280-4","article-title":"Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer","volume":"15","author":"Szijj","year":"2023","journal-title":"Nat Chem"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0014-3","article-title":"Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation","volume":"1","author":"Correnti","year":"2018","journal-title":"Leukemia"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0061","article-title":"Wesche H.TriTACs, a novel class of T-cell-engaging protein constructs designed for the treatment of solid tumors","volume":"20","author":"Austin","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy : current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.850358","article-title":"Emerging strategies in TCR-engineered T cells","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1493346","article-title":"TCR-T cell therapy for solid tumors : challenges and emerging solutions","volume":"16","author":"He","year":"2025","journal-title":"Front Pharmacol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1114770","article-title":"TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma","volume":"14","author":"Hussein","year":"2023","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1487782","article-title":"Clinical advances and challenges associated with TCR-T cell therapy for cancer treatment","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174160","article-title":"Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges","volume":"14","author":"Zhao","year":"2022","journal-title":"Cancers"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1018962","article-title":"Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango","volume":"13","author":"Kazemi","year":"2022","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1483254","article-title":"Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system","volume":"15","author":"V\u00f6lzke","year":"2024","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1450710","article-title":"A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE(R)) antibody construct, in patients with refractory solid tumors","volume":"7","author":"Kebenko","year":"2018","journal-title":"Oncoimmunology"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-306449","article-title":"Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma","volume":"117","author":"Moore","year":"2011","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2081-0","article-title":"A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice","volume":"67","author":"Fisher","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B71","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1080\/19420862.2015.1029216","article-title":"A tetravalent bispecific TandAb (CD19\/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells","volume":"7","author":"Reusch","year":"2015","journal-title":"MAbs"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00100","article-title":"Highly specific and effective targeting of EGFRvIII-positive tumors with TandAb antibodies","volume":"7","author":"Ellwanger","year":"2017","journal-title":"Frontiers in Oncology"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: Reversing a T-cell-induced immune escape mechanism","volume":"30","author":"Krupka","year":"2016","journal-title":"Leukemia"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19865","article-title":"CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice","volume":"8","author":"Horn","year":"2017","journal-title":"Oncotarget"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07195-w","article-title":"A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity","volume":"9","author":"Compte","year":"2018","journal-title":"Nature Communications"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194041","article-title":"Pre-Clinical Evaluation of AZD5492, a Novel CD8-Guided T Cell Engager, for B-Non Hodgkin Lymphoma Indications","volume":"144","author":"Lawrence","year":"2024","journal-title":"BLOOD"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00951-x","article-title":"Engineering strategies to enhance oncolytic viruses in cancer immunotherapy","volume":"17","author":"Tian","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2024-009901","article-title":"Engineered oncolytic virus expressing targeting BiTE enhances cell immune response","volume":"12","author":"Zhu","year":"2024","journal-title":"J ImmunoTher Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-51498-0","article-title":"Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy","volume":"15","author":"Taha","year":"2024","journal-title":"Nat Commun"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig","year":"2017","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.375","article-title":"Immunological synapse","volume":"19","author":"Bromley","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s40425-019-0807-6","article-title":"Duffy MR.Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples","volume":"7","author":"Scott","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1113303","article-title":"Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager","volume":"14","author":"Xiao","year":"2023","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0242","article-title":"MOR209\/ES414, a novel bispecific antibody targeting PSMA for the treatment of metastatic castration-resistant prostate cancer","volume":"15","author":"Hernandez-Hoyos","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1177\/17562872231182219","article-title":"Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer","volume":"15","author":"Zarrabi","year":"2023","journal-title":"Ther Adv Urol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adl2720","article-title":"Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6","volume":"16","author":"Stadler","year":"2024","journal-title":"Sci Transl Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0121314","article-title":"A mass spectrometric-derived cell surface protein atlas","volume":"10","author":"Bausch-Fluck","year":"2015","journal-title":"PloS One"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-0028","article-title":"Redirecting polyclonal T cells against cancer with soluble T-cell receptors","volume":"29","author":"Berman","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00909","article-title":"The natural cytotoxicity receptors in health and disease","volume":"10","author":"Barrow","year":"2019","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.19.8646","article-title":"A soluble, single-chain T-cell receptor fragment endowed with antigen-combining properties","volume":"88","author":"Novotny","year":"1991","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010477","article-title":"Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody","volume":"138","author":"Augsberger","year":"2021","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0770","article-title":"Reilly EB.ABBV-184: A novel survivin-specific TCR\/CD3 bispecific T-cell engager is active against both solid tumor and hematologic Malignancies","volume":"22","author":"Chervin","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1052090","article-title":"Kuball J.The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers","volume":"13","author":"van Diest","year":"2023","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04061-6","article-title":"Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs","volume":"599","author":"Yarmarkovich","year":"2023","journal-title":"Nature"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cei\/uxae031","article-title":"Disrupting B and T cell Collaboration in Autoimmune Disease : T cell engagers versus CAR T cell therapy","volume":"217","author":"Shah","year":"2024","journal-title":"Clin Exp Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041630","article-title":"Present and (Foreseeable) future of biological anti-TNF alpha therapy","volume":"12","author":"Leone","year":"2023","journal-title":"J Clin Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: A review in rheumatoid arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Clinical presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1267749","article-title":"Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study","volume":"14","author":"Yoshida","year":"2023","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v91i11-S.10311","article-title":"Tuberculosis and TNF-alpha inhibitors in children: how to manage a fine balance","volume":"91","author":"Parigi","year":"2020","journal-title":"Acta BioMed"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic","volume":"14","author":"de S\u00e8ze","year":"2023","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600089","article-title":"Features of human CD3+CD20+ T cells","volume":"197","author":"Schuh","year":"2016","journal-title":"J Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic Malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1181620","article-title":"Case Report: Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration","volume":"14","author":"Cao","year":"2023","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"e94263","DOI":"10.1172\/jci.insight.94263","article-title":"O\u2019Connor KCAutoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis","volume":"2","author":"Stathopoulos","year":"2017","journal-title":"JCI Insight"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"B112","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"Schett G.CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"B113","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"B114","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jtct.2022.10.004","article-title":"Successful generation of CD19 chimeric antigen receptor T cells from patients with advanced systemic lupus erythematosus","volume":"29","author":"Kretschmann","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.08.025","article-title":"Combination of rituximab with blinatumomab (MT103\/MEDI-538), a T cell-engaging CD19-\/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells","volume":"33","author":"d\u2019Argouges","year":"2009","journal-title":"Leuk Res"},{"key":"B116","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jtct.2024.03.023","article-title":"Fully human anti-CD19 CAR T cells derived from systemic lupus erythematosus patients exhibit cytotoxicity with reduced inflammatory cytokine production","volume":"30","author":"Dingfelder","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01375","article-title":"Identification of autoreactive B cell subpopulations in peripheral blood of autoimmune patients with pemphigus vulgaris","volume":"10","author":"Pollmann","year":"2019","journal-title":"Front Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1335998","article-title":"Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases","volume":"15","author":"Perico","year":"2024","journal-title":"Front Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1335998","article-title":"Corrigendum: Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases","volume":"15","author":"Perico","year":"2025","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/s41467-024-45854-3","article-title":"Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell Malignancies","volume":"15","author":"Ferrari","year":"2024","journal-title":"Nat Commun"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07233-2","article-title":"TRBC1-targeting antibody\u2013drug conjugates for the treatment of T cell cancers","volume":"628","author":"Nichakawade","year":"2024","journal-title":"Nature"},{"key":"B124","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12943-020-01282-7","article-title":"Pre-depletion of TRBC1+ T cells promotes the therapeutic efficacy of anti-TRBC1 CAR-T for T-cell Malignancies","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol Cancer"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830211202","article-title":"Fournier C.Therapy against murine collagen-induced arthritis with T cell receptor V beta-specific antibodies","volume":"21","author":"Chiocchia","year":"1991","journal-title":"Eur J Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.2337\/db11-0867","article-title":"Prevention of type 1 diabetes in the rat with an allele-specific anti-T-cell receptor antibody: V\u03b213 as a therapeutic target and biomarker","volume":"61","author":"Liu","year":"2012","journal-title":"Diabetes"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02613-z","article-title":"Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis","volume":"29","author":"Britanova","year":"2023","journal-title":"Nat Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05501-7","article-title":"Autoimmunity-associated T cell receptors recognize HLA-B*27-bound peptides","volume":"612","author":"Yang","year":"2022","journal-title":"Nature"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.14412\/1996-7012-2024-2-33-40","article-title":"Comparative analysis of the efficacy of seniprutug (BCD-180) and adalimumab in the treatment of active radiographic axial spondyloarthritis: results of a systematic review and matching-adjusted indirect comparison","volume":"18","author":"Lila","year":"2024","journal-title":"Modern Rheumatol J"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd3595","article-title":"TCR \u03b2 chain-directed bispecific antibodies for the treatment of T cell cancers","volume":"13","author":"Paul","year":"2021","journal-title":"Sci Transl Med"},{"key":"B131","doi-asserted-by":"publisher","first-page":"4334","DOI":"10.1038\/s41467-022-32092-8","article-title":"T cell receptor \u03b2-chain-targeting chimeric antigen receptor T cells against T cell Malignancies","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"B132","first-page":"1707","article-title":"TRBV9-targeted bispecific T cell-engaging antibodies to reset the autoreactive T cell compartment in spondyloarthritis and HLA-DQ8 celiac disease [abstract","volume":"76","author":"Glavaris","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903931","article-title":"Toxin-coupled MHC class I tetramers can specifically ablate autoreactive CD8+ T cells and delay diabetes in nonobese diabetic mice","volume":"184","author":"Vincent","year":"2010","journal-title":"J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1551424\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T09:35:17Z","timestamp":1746783317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1551424\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":133,"alternative-id":["10.3389\/fimmu.2025.1551424"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1551424","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"article-number":"1551424"}}